secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001493152-23-012125
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sigyn Therapeutics appoints Annette Marleau, Ph.D. as Chief Scientific Officer
------------------------------------------------------------------------------

- Appointed Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately.
- Previously CTO at Immunicom and Director of Research at Aethlon Medical, advancing blood purification for cancer.
- Awarded over $6 million in NIH grants; co-authored two FDA-cleared IDEs and a Breakthrough Device submission.
- Inventor on patents for blood purification therapies targeting cancer, inflammatory disorders, and infectious diseases.
- Her expertise supports Sigyn's pipeline including Sigyn Therapy, ChemoPrep, and ChemoPure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000149315223012125/0001493152-23-012125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000149315223012125/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer